AU2006287767B2 - IKK inhibitors for the treatment of endometriosis - Google Patents

IKK inhibitors for the treatment of endometriosis Download PDF

Info

Publication number
AU2006287767B2
AU2006287767B2 AU2006287767A AU2006287767A AU2006287767B2 AU 2006287767 B2 AU2006287767 B2 AU 2006287767B2 AU 2006287767 A AU2006287767 A AU 2006287767A AU 2006287767 A AU2006287767 A AU 2006287767A AU 2006287767 B2 AU2006287767 B2 AU 2006287767B2
Authority
AU
Australia
Prior art keywords
substituted
group
aryl
independently selected
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006287767A
Other languages
English (en)
Other versions
AU2006287767A1 (en
Inventor
Selvaraj Nataraja
Stephen S. Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2006287767A1 publication Critical patent/AU2006287767A1/en
Assigned to MERCK SERONO SA reassignment MERCK SERONO SA Alteration of Name(s) of Applicant(s) under S113 Assignors: LABORATOIRES SERONO S.A.
Application granted granted Critical
Publication of AU2006287767B2 publication Critical patent/AU2006287767B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006287767A 2005-09-07 2006-08-28 IKK inhibitors for the treatment of endometriosis Ceased AU2006287767B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71464505P 2005-09-07 2005-09-07
US60/714,645 2005-09-07
EP05109450.6 2005-10-10
EP05109450 2005-10-11
PCT/US2006/033686 WO2007030362A1 (en) 2005-09-07 2006-08-28 Ikk inhibitors for the treatment of endometriosis

Publications (2)

Publication Number Publication Date
AU2006287767A1 AU2006287767A1 (en) 2007-03-15
AU2006287767B2 true AU2006287767B2 (en) 2010-05-13

Family

ID=37663766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006287767A Ceased AU2006287767B2 (en) 2005-09-07 2006-08-28 IKK inhibitors for the treatment of endometriosis

Country Status (10)

Country Link
US (1) US20100069387A1 (https=)
EP (2) EP1931322B1 (https=)
JP (1) JP2009507073A (https=)
KR (1) KR20080052650A (https=)
CN (1) CN101304736A (https=)
AU (1) AU2006287767B2 (https=)
CA (1) CA2621057A1 (https=)
EA (1) EA200800755A1 (https=)
IL (1) IL189659A0 (https=)
WO (1) WO2007030362A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
CN101503402B (zh) * 2009-03-10 2014-06-25 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
CA2767914C (en) 2009-07-24 2020-02-25 Geadic Biotec, Aie. Markers for endometrial cancer
ES2577829T3 (es) 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Derivados de aminopirimidina como moduladores de la LRRK2
NO2638031T3 (https=) 2010-11-10 2018-03-10
US10729693B2 (en) 2018-03-02 2020-08-04 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN119769990B (zh) * 2024-12-26 2025-09-09 大连医科大学附属第二医院 子宫内膜异位症的检测系统和治疗剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046171A2 (en) * 2000-12-06 2002-06-13 Signal Pharmaceuticals, Inc. Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
WO2004007457A2 (en) * 2002-07-17 2004-01-22 Amgen Inc. Substituted benzylamine derivatives and methods of use
EP1424080A1 (en) * 2001-08-10 2004-06-02 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
WO2005034978A2 (en) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0160699B1 (en) 1983-11-02 1992-08-12 Applied Research Systems Ars Holding N.V. Production of heterodimeric human fertlity hormones
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
JP2002193938A (ja) * 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
PL364111A1 (en) * 2001-02-01 2004-12-13 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk)
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046171A2 (en) * 2000-12-06 2002-06-13 Signal Pharmaceuticals, Inc. Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
EP1424080A1 (en) * 2001-08-10 2004-06-02 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
WO2004007457A2 (en) * 2002-07-17 2004-01-22 Amgen Inc. Substituted benzylamine derivatives and methods of use
WO2005034978A2 (en) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gynaekologe (1997) 30(1) pp 581-594 *
Nature (5/11/98) 396(6706) pp 77-80 *
TW-Gynaekologie (1997) 10(6) pp 271-274 *

Also Published As

Publication number Publication date
KR20080052650A (ko) 2008-06-11
EA200800755A1 (ru) 2008-10-30
IL189659A0 (en) 2008-08-07
WO2007030362A1 (en) 2007-03-15
EP2266561A3 (en) 2011-05-18
AU2006287767A1 (en) 2007-03-15
CN101304736A (zh) 2008-11-12
EP1931322A1 (en) 2008-06-18
JP2009507073A (ja) 2009-02-19
EP2266561A2 (en) 2010-12-29
EP1931322B1 (en) 2012-08-15
CA2621057A1 (en) 2007-03-15
US20100069387A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
AU2006287767B2 (en) IKK inhibitors for the treatment of endometriosis
TW201808297A (zh) 子宮內膜病症治療劑之用法及用量
AU2006287765B2 (en) P13K inhibitors for the treatment of endometriosis
HK1152647A (en) Ikk inhibitors for the treatment of endometriosis
US8658640B2 (en) JNK inhibitors for the treatment of endometriosis
MX2008002908A (es) Inhibidores de ikk para el tratamiento de endometriosis
BRPI0615700A2 (pt) uso de um inibidor ikk na fabricação de um medicamento para o tratamento e/ou prevenção de endometriose em um indivìduo
AU2006270184B2 (en) JNK inhibitors for the treatment of endometreosis
CN101300047A (zh) Pi3k抑制剂用于子宫内膜异位症的治疗
AU2011265521B9 (en) JNK inhibitors for the treatment of endometreosis
HK1119103A (zh) 治疗子宫内膜异位症的jnk抑制剂
CN101262906A (zh) 治疗子宫内膜异位症的jnk抑制剂
HK1123234A (en) Pi3k inhibitors for the treatment of endometriosis
KR20080052641A (ko) 자궁내막증 치료용 ｐｉ３ｋ 억제제

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 60/714,645 07 SEP 2005 US AND 05109450.6 11 OCT 2005 EP

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired